Clin2
NCT05458492Possibly a fitNot yet recruiting

Sirolimus for moderate-to-severe facial skin sarcoidosis

SarcoidosisCutaneous Sarcoidosis

Treatments studied

Part of Blood & lymphatic, Immune system & allergy clinical trials.

This trial studies whether sirolimus (an immune-influencing medicine) can improve moderate-to-severe sarcoidosis affecting the face. It may help if you’ve tried standard sarcoidosis treatments before but they didn’t work well enough or stopped working.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
18 years to 74 years
Study type
Interventional

Who can take part

  • You are 18 to 74 years old and can give informed consent
  • You have confirmed sarcoidosis in facial skin (face lesions confirmed by biopsy)
  • Your facial sarcoidosis is moderate-to-severe based on doctor scoring and overall assessment
  • You must have health coverage and be willing/able to follow study instructions reliably
  • You are not pregnant or breastfeeding, and you can use effective birth control during treatment and for 12 weeks after stopping (if you could become pregnant)
  • You cannot have certain liver problems, certain allergies (including peanut/soy), uncontrolled high blood pressure, or active infections (including tuberculosis)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06978725Recruiting· Phase 2/Phase 3
Brepocitinib for skin sarcoidosis

This study tests an oral drug called brepocitinib to see if it can help people with skin sarcoidosis and reduce skin symptoms. It aims to find a better treatment option for this condition.

San Francisco, California
NCT03593759Recruiting· Phase 3
Testing treatment for active cardiac sarcoidosis heart rhythm and function

This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.

New Haven, Connecticut
NCT04736953Not yet recruiting· Phase 2
Sirolimus for active lupus symptoms in adults

This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.

NCT05841758Recruiting· Phase 4
Hydroxychloroquine to reduce steroid use in sarcoidosis

This trial studies whether hydroxychloroquine can control extrapulmonary sarcoidosis (sarcoidosis outside the lungs) using less steroid treatment. It may help people who need systemic therapy for problems such as eyes, skin, bones, joints, nerves, ENT areas, or high calcium levels from sarcoidosis.

Avignon
NCT06660732Recruiting· Phase 2
Study of Rilonacept for cardiac sarcoidosis

This trial tests if rilonacept can help people with cardiac sarcoidosis, a condition where inflammation affects the heart. You may join if you have active inflammation on a PET scan despite standard treatments.

Baltimore, Maryland
NCT04047576Recruiting· Phase 2/Phase 3
Sirolimus for unknown-cause retroperitoneal scarring

This trial tests sirolimus to treat idiopathic (unknown-cause) retroperitoneal fibrosis, a condition where scar tissue forms in the belly behind the kidneys. You may be considered if imaging and blood tests suggest active inflammation, and if you’re able to safely take the study medicine and return for follow-up.

Beijing, Beijing Municipality

Hear when a new Sarcoidosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.